Value2020202120232024TTMSelling/general/admin expenses7.13 M9.43 M21.06 M26.61 M31.53 MResearch & development1.43 M2.58 M21.31 M41.64 M64.17 MOperating income-3.45 M-7.39 M-40.94 M-90.89 M-118.72 MNon-Operating Income, Total59 K119 K835 K10.46 M10.3 MInterest expense, net of interest capitalized——84 K——Non-Operating Income, excl. Interest Expenses59 K119 K749 K10.46 M8.9 MUnusual income/expense0—2 000——Pretax income3.5 M7.51 M-40.11 M-80.43 M-108.41 MEquity in earnings——-17 K-8 000-3 000Taxes00-2.65 M-2.1 M—Non-controlling/minority interest—————After tax other income/expense———-34 K-66 KNet income before discontinued operations-3.39 M-7.27 M-55.56 M-80.23 M-106.31 MDiscontinued operations——9.05 M949 K514 KNet income-3.39 M-7.27 M-46.51 M-79.28 M-105.8 MDilution adjustment6.78 M14.54 M———Preferred dividends3 0000———Diluted net income available to common stockholders3.39 M7.27 M46.51 M79.28 M105.8 MBasic earnings per share (Basic EPS)—-0.5-1.7-1.23-1.48Diluted earnings per share (Diluted EPS)—-0.51-1.74-1.23-1.48Average basic shares outstanding—14.2 M26.76 M64.42 M283.72 MDiluted shares outstanding—14.2 M26.76 M64.42 M283.72 MEBITDA-3.26 M-7.1 M-38.82 M——EBIT-3.45 M-7.39 M-39.8 M——Cost of revenue4.93 M6.18 M298 K——Other cost of goods sold——298 K——Depreciation & amortization (cash flow)186 K289 K986 K7 000—
Perspective Therapeutics Inc
Isoray Inc. is a national isotope-based medical company and the sole producer of Cesium brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is a registered manufacturer with the FDA and holds multiple 510 clearances for brachytherapy devices. The brachytherapy isotopes are sold under the brandname Blu.
The company went public in 2005. Isoray’s corporate headquarters is located at 350 Hills Street, Suite 106, Richland WA 99354.